Collaboration, License, and Other Agreements - North America - General Information (Details) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
|
Jun. 30, 2026
USD ($)
|
Jun. 30, 2025
USD ($)
|
Jun. 30, 2026
USD ($)
item
|
Jun. 30, 2025
USD ($)
|
|
| Collaboration, License, Promotion and Other Commercial Agreements | ||||
| Research and development expense | $ 22,421 | $ 23,373 | $ 44,361 | $ 50,805 |
| AbbVie Plc | ||||
| Collaboration, License, Promotion and Other Commercial Agreements | ||||
| Remaining commercial-period performance obligations | item | 3 | |||
| Cost sharing amount, reduction to research and development | 100 | 1,700 | $ 300 | 2,800 |
| Collaborative arrangement, percentage of obligation of development costs incurred | 50.00% | |||
| Percentage of net profit from commercialization (as a percent) | 50.00% | |||
| Percentage of net loss from commercialization (as a percent) | 50.00% | |||
| North America | AbbVie Plc | ||||
| Collaboration, License, Promotion and Other Commercial Agreements | ||||
| Research and development expense | $ 2,400 | $ 1,400 | $ 3,700 | $ 3,200 |